Remove 2018 Remove Clinic Remove PET Scan
article thumbnail

New portable PET scanner tested in humans

AuntMinnie

Clinical brain imaging with a newly developed portable PET scanner appears feasible, with a comparison to conventional PET imaging for the first time revealing similar results in human subjects, according to a group in New York City. In 2018, the group received a grant from the U.S.

article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Imaging Technology

CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Measurement follows NEMA NU 2-2018. [v] iv] Omni Legend 32 cm has up to 2.2 ix Mehranian, A.,

article thumbnail

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

The ability to determine the extent and location of recurrent prostate cancer to inform appropriate clinical management for these men is key for physicians and their patients, because up to 50% of patients who undergo radiation therapy will develop local or distant recurrences within 10 years,” said Brian T. across all regions.

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

All of us at Blue Earth Diagnostics want to express our sincere gratitude to the many patients, physicians, clinical trial sites and collaborators who have worked closely with us to progress POSLUMA.” Results demonstrated high detection rates (% positive PET scans) even at low PSA levels.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.

article thumbnail

AI Could Help Doctors Diagnose Lung Cancer Earlier

Imaging Technology

The performance improved on the Brock score, a test currently used in clinic, which scored 0.672. The new model also performed comparably to the Herder score, another test currently used in clinic, which had an AUC of 0.83. size, location, spiculation status), but also includes PET scan findings.